The HbA1c reduction, as with other antihyperglycaemic agents depends largely on the patient population studied, the baseline glycaemic situation at the beginning of the observation and the concomitant therapy, including life-style intervention (12, 19, 21, 22)
Some studies (like a recent one tracking over 18,000 adults)suggest that tirzepatide (used in Mounjaro and Zepbound), may lead to slightly more weight loss on average than semaglutide (in Wegovy, Ozempic, and Rybelsus)
What are the common and serious adverse effects of GLP1 receptor agonists (e.g., exenatide, liraglutide, semaglutide, dulaglutide, tirzepatide) and how should they be managed?
Otherwise, combined use is well-tolerated at standard doses